Kodiak Sciences said its two late-stage eye therapies for wet age-related macular degeneration achieved statistical equivalence to Regeneron’s Eylea in a Phase 3 trial. The company reported that individualized dosing helped sustain efficacy while reducing injection frequency for many patients, positioning Zenkuda as a potential durability-focused alternative in retinal care. Kodiak said more than half of trial participants in the Zenkuda arm received injections only once every six months, compared with once every eight weeks for Eylea. The company also reported its second asset, tabirafusp alfa tedromer, matched Eylea using the same individualized approach. Kodiak plans to seek FDA approval for Zenkuda and expand into additional indications for other eye disorders in the fourth quarter of 2026. The result marks a turnaround for Zenkuda after an earlier Phase 3 readout that failed to match Eylea, which Kodiak linked to patient dosing needs and the trial’s earlier approach to dosing.